Company Profile

VIVIMED LABS LTD.

NSE : VIVIMEDLABBSE : 532660ISIN CODE : INE526G01021Industry : Pharmaceuticals & DrugsHouse : Private
BSE15.45-0.25 (-1.59 % )
PREV CLOSE (Rs.) 15.70
OPEN PRICE (Rs.) 15.50
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 139848
TODAY'S LOW / HIGH (Rs.)15.20 16.05
52 WK LOW / HIGH (Rs.)6.5 23.62
NSE15.55 -0.1 (-0.64 % )
PREV CLOSE(Rs.) 15.65
OPEN PRICE (Rs.) 15.30
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 15.55 (3617 )
VOLUME 727872
TODAY'S LOW / HIGH(Rs.) 15.15 16.10
52 WK LOW / HIGH (Rs.)6.2 23.35

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.00
TTM EPS (Rs.) -1.18
P/E Ratio 0.00
Book Value (Rs.) 62.33
Face Value (Rs.) 2
MCap (Rs. in Mn) 1281.02
Price/Earning (TTM) 21.54
Price/Sales (TTM) 0.56
Price/Book (MRQ) 0.25
PAT Margin (%) -6.93
ROCE (%) 2.67
Incorporation Year : 1988

Management Info :

Bhagvanth Rao Mamidpalli - Chairman Santosh Varalwar - Managing Director

Registered Office :

Address : Plot No 78 - A,Kolar Industrial Area, ,
Bidar,
Karnataka-585403

Phone : 08482-232045

Registrar's Details : Aarthi Consultants Pvt Ltd
1-2-285 ,Domalaguda,,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
22Feb02-22-2021$Vivimed Labs gets approval for 1 product from Uzbekistan Government Vivimed Labs gets approval f

Vivimed Labs has received approval for 1 product from Uzbekistan Government for its PICS & Health Canada approved site, both facilities are situated at Hyderabad. The product is Paracetamol 125 mg/5mL + Chlorpheniramine Maleate 2.5 mg/5mL syrup under brand name FEBRIL Syrup 100ml.

Paracetamol is also known as acetaminophen, is a medication used to treat pain and fever. Chlorpheniramine is an antihistamine used to relieve symptoms of allergy, hay fever, and the common cold. 

Vivimed Labs is engaged in providing specialty chemicals and pharmaceuticals products. The company offers products for oral care, sun care, skin care, hair care, reversacol photochromic dyes, imaging chemicals and nisarg.

Vivimed Labs has received approval for 1 product from Uzbekista..
22Feb02-22-2021$Vivimed Labs zooms on getting approval for 1 product from Uzbekistan Government Vivimed Labs zooms on gettin

Vivimed Labs is currently trading at Rs. 15.90, up by 1.05 points or 7.07% from its previous closing of Rs. 14.85 on the BSE.

The scrip opened at Rs. 14.85 and has touched a high and low of Rs. 16.15 and Rs. 14.60 respectively. So far 77849 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 23.62 on 25-Aug-2020 and a 52 week low of Rs. 6.50 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 16.90 and Rs. 14.40 respectively. The current market cap of the company is Rs. 131.00 crore.

The promoters holding in the company stood at 32.79%, while Institutions and Non-Institutions held 3.22% and 63.99% respectively.

Vivimed Labs has received approval for 1 product from Uzbekistan Government for its PICS & Health Canada approved site, both facilities are situated at Hyderabad. The product is Paracetamol 125 mg/5mL + Chlorpheniramine Maleate 2.5 mg/5mL syrup under brand name FEBRIL Syrup 100ml.

Paracetamol is also known as acetaminophen, is a medication used to treat pain and fever. Chlorpheniramine is an antihistamine used to relieve symptoms of allergy, hay fever, and the common cold.

Vivimed Labs is engaged in providing specialty chemicals and pharmaceuticals products. The company offers products for oral care, sun care, skin care, hair care, reversacol photochromic dyes, imaging chemicals and nisarg.

Vivimed Labs is currently trading at Rs. 15.90, up by 1.05 poin..
01Feb02-01-2021$ Board Meeting Intimation for Notice Of Board Meeting / Closure Of Trading Window Board Meeting Intimation fo
VIVIMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations & Disclosure Requirements), 2015, further to our letter dated 30.12.2020, we hereby bring to your notice that the meeting of the Board of Directors of the Company is scheduled to be held on Saturday, 13th Day of February, 2021 at Hyderabad inter alia to consider and approve, un-audited Financial Results (Standalone & Consolidated) of the company for the quarter and nine months ended 31st December, 2020. Further, we would like to inform that pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the company has intimated its 'Designated Persons including Directors' regarding the closure of trading window from 01.01.2021 to till 48 hours after the declaration of un-audited Financial Results (Standalone & Consolidated) of the company for the quarter and nine months ended 31st December, 2020. Kindly take the above information on records.
VIVIMED LABS LTD.has informed BSE that the meeting of the Board..
16Dec12-16-2020$ Intimation Of Sale Of Shares Of Wholly Owned Subsidiary Company Intimation Of Sale Of Share
Intimation of Sale of shares of wholly Owned Subsidiary Company
Intimation of Sale of shares of wholly Owned Subsidiary Company
02Dec12-02-2020$ Announcement under Regulation 30 (LODR)-Demise Announcement under Regulati
Intimation under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') - Sad Demise of Independent Director
Intimation under the SEBI (Listing Obligations and Disclosure R..
Financials More
Rs. in Millions
QTR Dec 20 ANNUAL 20
Net Profit2.05000000000005-191.700000000001
Gross Profit 2.05000000000005 -207.4
Operating Profit 152.88388.27
Net Sales 624.392766.06
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Sanofi India (BSE)
 8268.85 (1.40%)
M.Cap ( in Cr)
19043.68
Abbott India (BSE)
 14396.65 (0.34%)
M.Cap ( in Cr)
30591.88
Orchid Pharma (BSE)
 885.15 (5.00%)
M.Cap ( in Cr)
3612.86
Alembic Pharma (BSE)
 919.15 (2.38%)
M.Cap ( in Cr)
18067.10
Natural Capsules (BSE)
 117.40 (19.98%)
M.Cap ( in Cr)
73.17
Shareholding Pattern More
NON-INSTITUTION 63.99 %
PROMOTERS 32.79 %
GOVERNMENT 0.12 %
MUTUAL FUNDS/UTI 0 %
FI/BANKS/INSURANCE 0 %
FII 0 %
MF HOLDINGS More
Scheme NameHold(%)
Edelweiss Mid Cap Fund-...0.45
F & O Quotes